5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine, 95.0%, 100g

2,5-Dichlorobenzamide, 95.0%, 5g

N-(3-aminophenyl)-2-methoxybenzamide, 95.0%, 1g

3-[(dimethylamino)methyl]-4-fluorobenzoic acid, 95%, 50mg

5-(2-Chloro-phenyl)-isoxazole-3-carboxylic acid methyl ester, 95.0%, 100mg

1-Methyl-4-methylaminopiperidine dihydrochloride, 98.0%, 1g

3-Bromo-2-chloro-5-nitropyridine, 98.0%, 100g

(S)-tert-Butyl (1-amino-3-(4-bromophenyl)-1-oxopropan-2-yl)carbamate, 95+%, 250mg

(R)-2-(4-((2-Aminobutyl)amino)pyrimidin-2-yl)-4-(1-methyl-1H-pyrazol-4-yl)phenol dihydrochloride, 98+%, 25mg

2,7-Bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrene>97.0%(GC)5g

Sistema de vacío MD 4 serie MD 4C NT +AK+EK, 1 pieza

1,2,3,6,7,8-Hexahydro-as-indacen-4-amine, 98%, 250mg

2-Amino-N-(1,2,3,4-tetrahydronaphthalen-1-yl)acetamide, 98%, 250mg